| CITIUS PHARMACEUTICALS |
| USA |
| Gesundheit |
| US17322U3068 / A40MD0 |
| 47N0 (Frankfurt) / CTXR (NASDAQ) |
| FRA:47N0, ETR:47N0, 47N0:GR, NASDAQ:CTXR |
| - |
| https://www.citiuspharma... |
|
Citius Pharmaceuticals, Inc. is a late-stage biopharmaceutical company specializing in the development and commercialization of first-in-class critical care products. The company focuses on innovative therapies primarily in anti-infectives, oncology,..
>Volltext.. |
| 16.56 Mio. EUR |
| 23.16 Mio. EUR |
| 3.42 Mio. EUR |
| -31.87 Mio. EUR |
| -31.09 Mio. EUR |
| -2.51 EUR |
| 1.59 Mio. EUR |
| 6.69 Mio. EUR |
| -30.18 Mio. EUR |
| 0.2 |
| - |
| 9.55% |
| - |
| - |
| - |
| - |
| CITIUS PHARMACEUTICALS, CITIUS PHARMA, CITIUS PHARMACEUTICAL |
| 04.04.26 |
|